Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellerix SA

Division of Takeda Pharmaceutical Co. Ltd.
www.cellerix.com

Latest From Cellerix SA

TiGenix to receive €5 million loan for Phase III Crohn's trial

TiGenix' wholly-owned subsidiary, Cellerix, is to receive nearly €5 million in a soft loan from the "Madrid Network" to finance a Phase III fistula programme in Crohn's disease.

Gastrointestinal Spain

Regenerative medicine – time to cut through the hype

Regenerative medicine is widely seen as playing a vital future role in difficult-to-treat conditions like diabetes, Parkinson's disease and stroke. But can it really deliver on its promise, or is it simply being hyped up to persuade investors to put money into what is a young and unpredictable area of research?

Gastrointestinal Metabolic Disorders

Deals Shaping the Medical Industry (04/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

TiGenix bulks up in merger with Cellerix

Belgian firm TiGenix has agreed to merge with Cellerix, a Spanish company specialising in adipose tissue-derived stem cell therapies, in a bid to gain critical mass in the regenerative medicine market.

Gastrointestinal Dermatology
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Immune Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Spain
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Eduardo Bravo, CEO
    Claudia D'Augusta, PhD, CFO
    Jose Luis Bravo, MD, PhD, VP, Global Medical, R&D
  • Contact Info
  • Cellerix SA
    Phone: (34) 91 804 92 64
    Calle Marconi, 1
    Tres Cantos
    Madrid, 28760
    Spain
Advertisement
Advertisement
UsernamePublicRestriction

Register